- Home
- IPXX vs RVNC Comparison
IPXX vs RVNC Comparison
Compare IPXX & RVNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPXX
- RVNC
- Stock Information
- Founded
- IPXX 2023
- RVNC 1999
- Country
- IPXX United States
- RVNC United States
- Employees
- IPXX N/A
- RVNC N/A
- Industry
- IPXX Blank Checks
- RVNC Biotechnology: Pharmaceutical Preparations
- Sector
- IPXX Finance
- RVNC Health Care
- Exchange
- IPXX Nasdaq
- RVNC Nasdaq
- Market Cap
- IPXX 337.5M
- RVNC 320.5M
- IPO Year
- IPXX 2023
- RVNC 2014
- Fundamental
- Price
- IPXX $10.99
- RVNC $3.09
- Analyst Decision
- IPXX
- RVNC Hold
- Analyst Count
- IPXX 0
- RVNC 9
- Target Price
- IPXX N/A
- RVNC $8.45
- AVG Volume (30 Days)
- IPXX 14.0K
- RVNC 3.6M
- Earning Date
- IPXX 01-01-0001
- RVNC 11-07-2024
- Dividend Yield
- IPXX N/A
- RVNC N/A
- EPS Growth
- IPXX N/A
- RVNC N/A
- EPS
- IPXX 0.37
- RVNC N/A
- Revenue
- IPXX N/A
- RVNC $256,945,000.00
- Revenue This Year
- IPXX N/A
- RVNC $11.28
- Revenue Next Year
- IPXX N/A
- RVNC $27.21
- P/E Ratio
- IPXX $29.42
- RVNC N/A
- Revenue Growth
- IPXX N/A
- RVNC 25.82
- 52 Week Low
- IPXX $10.31
- RVNC $2.30
- 52 Week High
- IPXX $15.18
- RVNC $9.75
- Technical
- Relative Strength Index (RSI)
- IPXX 44.61
- RVNC 33.47
- Support Level
- IPXX $10.76
- RVNC $3.06
- Resistance Level
- IPXX $15.18
- RVNC $3.09
- Average True Range (ATR)
- IPXX 0.86
- RVNC 0.11
- MACD
- IPXX -0.16
- RVNC 0.02
- Stochastic Oscillator
- IPXX 5.23
- RVNC 6.90
About IPXX Inflection Point Acquisition Corp. II
Inflection Point Acquisition Corp II is a blank check company. It is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About RVNC Revance Therapeutics Inc.
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.